Kupando Raises €10 Million to Reimagine Cancer Treatment
German biotech company Kupando has secured €10 million in new funding to advance a novel cancer therapy platform inspired by the way animals naturally defend themselves against disease. The investment underscores growing confidence in next-generation immuno-oncology approaches that aim to harness and enhance the body’s own immune system to fight tumors.
Animal Immunity as a Blueprint for Human Therapies
Kupando is developing drug candidates that mimic powerful defense mechanisms seen in animals with unusually high resistance to cancer and infections. By decoding these natural strategies, the company aims to design targeted therapies that can trigger a more robust and durable anti-tumor response in humans.
The platform focuses on modulating key components of the innate immune response and integrating them with the body’s adaptive immunity. This dual approach is intended to help patients’ immune cells recognize tumors earlier, attack them more effectively, and potentially prevent relapse.
Funding to Accelerate Preclinical and Early Clinical Work
The €10 million round will be used to expand Kupando’s preclinical pipeline, strengthen its core research team, and prepare its lead candidates for first-in-human trials. The company plans to prioritize indications where existing cancer therapies—such as checkpoint inhibitors and chemotherapy—have limited efficacy or cause severe side effects.
Investors are betting that an animal-immunity-inspired framework could open new therapeutic avenues for patients with resistant solid tumors and hematological cancers. The funding will also support partnerships with academic centers and clinical networks in Europe to validate the platform and design rigorous trial protocols.
Positioning Within Europe’s Biotech Landscape
With this raise, Kupando joins a growing cohort of European BioTech startups pushing the frontier of precision medicine and immune-based therapies. The company’s strategy aligns with a broader shift in oncology R&D toward mechanism-driven, biology-first approaches that leverage cross-species insights.
If successful, Kupando’s research could contribute to a new class of treatments that are more effective, more targeted, and less toxic than many current standards of care, offering fresh hope to patients facing aggressive and treatment-resistant cancers.